High-Efficiency Targeted Mitochondrial Transfer and AUTAC4-Enhanced Dual Renewal Strategy for Rheumatoid Arthritis - PubMed
7 days ago
- #AUTAC4
- #Rheumatoid Arthritis
- #Mitochondrial Transfer
- The article introduces a novel biomimetically engineered carrier material for treating Rheumatoid Arthritis (RA) using mitochondria as 'living materials'.
- The carrier features a folic acid-modified macrophage membrane for targeted delivery to M1 macrophages in RA joints, enhancing delivery efficiency by more than twofold.
- It incorporates AUTAC4 to selectively destroy dysfunctional mitochondria, achieving complete mitochondrial renewal and improving energy metabolism and homeostasis.
- The Dual-Action Mitochondrial Renewal Therapy (DAMRT) demonstrated significant therapeutic potential in an RA model.
- This approach addresses limitations of conventional biomaterials, such as lack of targeted accuracy, delivery efficiency, and biocompatibility.
- The therapy could serve as a new platform for treating RA and other mitochondrial dysfunctions.